Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 6/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 6/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 6/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.39 |
| ▸ | GABRP | O00591 | 5/20 | 0.39 |
| ▸ | GABRD | O14764 | 5/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 5/20 | 0.39 |
| ▸ | GABRE | P78334 | 5/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 5/20 | 0.39 |
| ▸ | GABRG3 | Q99928 | 5/20 | 0.39 |
| ▸ | GABRQ | Q9UN88 | 5/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2950960 | 0.92 | ALDH1A1 (0.40) | ALDH1A1TDP1CNR2GABRA2GABRA1 | |
| SCHEMBL2945250 | 0.91 | GABRA1 (0.43) | ALDH1A1TDP1CNR2GABRA2GABRA1 | |
| SCHEMBL2945342 | 0.90 | PTGER1 (0.42) | ALDH1A1TDP1PTGDR2FSCN1PTGER1 | |
| SCHEMBL2943369 | 0.90 | CNR2 (0.43) | ALDH1A1TDP1CNR2GABRA2GABRA1 | |
| SCHEMBL2943244 | 0.88 | FSCN1 (0.40) | ALDH1A1TDP1PTGDR2FSCN1ALKBH1 | |
| SCHEMBL1684271 | 0.88 | FSCN1 (0.37) | ALDH1A1TDP1PTGDR2FSCN1PTGER1 | |
| SCHEMBL2943248 | 0.88 | ALDH1A1 (0.40) | ALDH1A1TDP1CNR2GABRA2GABRA1 | |
| SCHEMBL2948096 | 0.87 | PDE10A (0.40) | ALDH1A1TDP1PTGDR2FSCN1PTGER1 | |
| SCHEMBL4805906 | 0.85 | ALDH1A1 (0.43) | ALDH1A1TDP1CNR2GABRA2GABRA1 | |
| SCHEMBL4804162 | 0.83 | FSCN1 (0.40) | PTGDR2FSCN1ALKBH1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558611-B1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER (US) | 2010-01-06 | — | — | EP | disclosed |
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC | 2008-09-11 | — | — | US | disclosed |
| US-7368571-B2 | HIV-Integrase inhibitors, pharmaceutical compositions and methods for their use | PFIZER INC (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070004768-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-7135482-B2 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1558611-A2 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040147547-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004039803-A2 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147547-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | IMPDH1, POLA1, POLB | ALDH1A1 794/4885TDP1 66/4885CNR2 4649/4885 |
| US-20070004768-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | TYMP, IMPDH1, POLB | ALDH1A1 1133/4885TDP1 108/4885CNR2 4607/4885 |
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | TYMP, IMPDH1, POLB | ALDH1A1 1208/4885TDP1 102/4885CNR2 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.